Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry - Top-Institutions - MDSpire

Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry

  • By

  • Pedro Horna

  • Matthew J. Weybright

  • Mathieu Ferrari

  • Dennis Jungherz

  • YaYi Peng

  • Zulaikha Akbar

  • F. Tudor Ilca

  • Gregory E. Otteson

  • Jansen N. Seheult

  • Janosch Ortmann

  • Min Shi

  • Paul M. Maciocia

  • Marco Herling

  • Martin A. Pule

  • Horatiu Olteanu

  • February 29, 2024

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematopathology
    • Immunology
    • Flow Cytometry
    • Cancer Immunotherapy

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Flow Cytometry
    • Molecular Diagnostics

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Immunotherapy
    • Flow Cytometry
    • Molecular Pathology

  • #4

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Immunology
    • Hematopathology
    • Flow Cytometry
    • Cellular Therapy

  • #5

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Hematology
    • Immunotherapy
    • Flow Cytometry
    • Molecular Medicine

Original Source(s)

Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry

  • by Pedro Horna, Matthew J. Weybright, Mathieu Ferrari, Dennis Jungherz, YaYi Peng, Zulaikha Akbar, F. Tudor Ilca, Gregory E. Otteson, Jansen N. Seheult, Janosch Ortmann, Min Shi, Paul M. Maciocia, Marco Herling, Martin A. Pule, Horatiu Olteanu

  • February 29, 2024

Related Content

Delays in Diagnosis of Hematological Cancers in Children: An Analysis of Symptom Recognition to Diagnosis Timeline and Contributing Factors at a Tertiary Hospital in Uganda

Molecular Pathology Insights into Hematologic Malignancies: An In-Depth Analysis of Genetic and Chromosomal Abnormalities and Their Clinical Implications

Morristown Medical Center: Leading Edge Research in CAR-T and TIL therapy

Morristown Medical Center now offers patients access to innovative clinical trials for immunotherapies including the use of Chimeric Antigen Receptor T Cells (CAR-T) and Tumor Infiltrating Lymphocytes (TIL).

  • by

  • March 11, 2024

  • 2 min